The US Food and Drug Administration (FDA) has approved the subcutaneous administration of vedolizumab (Entyvio) for maintenance therapy in adults with moderately to severely active Crohn's disease (CD ...

Credit: Takeda. The approval was based on data from the phase 3 VISIBLE 2 trial. Results showed 48% of patients treated with vedolizumab SC were in clinical remission at week 52 compared with 34% of ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved subcutaneous administration of Takeda Pharmaceuticals’ Entyvio for maintenance therapy in ...

− ENTYVIO Is the Only FDA-Approved Ulcerative Colitis Biologic That Offers the Choice of Intravenous or Subcutaneous Maintenance Therapy “With the FDA approval of subcutaneous ENTYVIO, patients and ...

Vedolizumab (Entyvio) was more effective at inducing remission in patients with chronic pouchitis after ileal pouch-anal anastomosis (IPAA) for ulcerative colitis compared with placebo, a randomized ...

Approximately half the patients with ulcerative colitis who undergo restorative proctocolectomy with ileal pouch–anal anastomosis (IPAA) will subsequently have pouchitis, and among those patients, one ...

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its Biologics License ...

12% of people with ulcerative colitis need surgery to have their colon removed (colectomy). Most of those have an ileo-anal pouch surgically constructed from their small bowel, which means that they ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The risankizumab cohort had higher 52-week clinical ...